Novo Nordisk trims forecast on US headwinds
This article was originally published in Scrip
Novo Nordisk has reported weaker than expected first quarter results. Sales grew by 7% in local currencies to DKK20.3bn, meaning the world's biggest insulin manufacturer failed to report quarterly double-digit sales growth for the first time in 12 years. The Danish company has now trimmed its forecast for full-year sales growth from 8-11% to 7-10%.